Scantox Group

Scantox is a preclinical GLP-accredited CRO, specialized in providing services within the drug development process Discovery, Genetic Toxicology, Regulatory Toxicology and Pharmaceutical Development & Analytical. Based on decades of experience, we are a trusted partner for CRO services for the pharmaceutical and medical devices industries. The Scantox Group is headquartered in Ejby, Denmark, with subsidiaries in UK, Austria, Denmark and Sweden (Lund and Gothenburg). The Scantox services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards. The Scantox team is passionate about the common vision to improve the health of people, and all processes are rooted in dedication and guided by a strong sense of purpose. Founded in 1977, Scantox is today owned by the Nordic based investment company Impilo. Certified as a 2023 Great Place To Work™.#pharmacology #toxicology #histopathology #pathology #minipigtoxicology #neuropharmacology #genotox